Association Between Tumor Necrosis Factor Inhibitors and the Risk of Hospitalization or Death Among Patients With Immune-Mediated Inflammatory Disease and COVID-19
Zara Izadi(University of California, San Francisco), Philippe Goupille(Université de Tours), Enrique R. Soriano(American Institute of Biological Sciences), Kristin M. D’Silva(Brigham and Women's Hospital), Tiffany Hsu(Baylor College of Medicine), Maria O Valenzuela-Almada(Mayo Clinic), Nick Dand(King's College London), Jean‐Frédéric Colombel(Mount Sinai Hospital), Pascal Claudepierre(Hôpitaux Universitaires Henri-Mondor), Zenas Z N Yiu(Manchester University NHS Foundation Trust), Saskia Lawson‐Tovey(Manchester Academic Health Science Centre), Marta Caprioli, Jeffrey A. Sparks(Brigham and Women's Hospital), Eva Klingberg(University of Gothenburg), Anja Strangfeld(German Rheumatism Research Centre), Alí Duarte‐García(Mayo Clinic in Arizona), Naomi J. Patel(Evidence (Italy)), C. A. Isnardi, Leanna Wise(University of Southern California), Ryan C. Ungaro(Feinstein Institute for Medical Research), Cláudia Diniz Lopes Marques(Universidade Federal de Pernambuco), Kimme L Hyrich(Manchester Royal Infirmary), Gabriela Schmajuk(San Francisco VA Medical Center), Milena Gianfrancesco(Pfizer (United States)), Mark Yates(King's College London), Ana Rita Cruz-Machado(University of Lisbon), Bimba F. Hoyer(German Rheumatism Research Centre), Erica J. Brenner(University of North Carolina Health Care), Satveer K. Mahil(Guy's and St Thomas' NHS Foundation Trust), Patricia Katz(University of California, San Francisco), Emily Gilbert(Jacksonville College), Adriana María Kakehasi(Universidade Federal de Minas Gerais), Rosana Quintana(Hospital Provincial de Rosario), Laura Trupin(University of California, San Francisco), Rebecca Hasseli(Kerckhoff Klinik), Elsa F Mateus(Portuguese League Against Epilepsy), Hanns‐Martin Lorenz, Andrea M. Seet(University of California, San Francisco), Ricardo Machado Xavier(Universidade Federal do Rio Grande do Sul), René‐Marc Flipo(Université de Lille), Giovanna Cuomo(Regione Campania), Alexander Pfeil(Jena University Hospital), Xian Zhang(AST Products (United States)), Samar Al Emadi(Weill Cornell Medical College in Qatar), Stephanie Rush(University of California, San Francisco), A. Cantagrel(Hôpital Rangueil), Lindsay Jacobsohn(University of California, San Francisco), Loreto Carmona(Instituto de Salud Musculoesquelética), Ana Carolina Mazeda Pereira(Centro Hospitalar do Baixo Vouga), Manasi Agrawal(Aalborg University)
Cited by 117
Related Papers
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2005|3.9k
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update
|Annals of the Rheumatic Diseases|2020|2.8k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k